Insulin resistance: Genetic associations with depression and cognition in population based cohorts
By S. Frangou, M. Shirali, Mark J. Adams, David M. Howard, J. Gibson, L. Hall, Blair H. Smith, S. Padmanabhan, Alison D Murray, David J. Porteous and 4 more. Experimental Neurology, 2019
807 citations recorded by the source corpus.
&NA; Insulin resistance, broadly defined as the reduced ability of insulin to exert its biological action, has been associated with depression and cognitive dysfunction in observational studies. However, it is unclear whether these associations are causal and whether they might be underpinned by other shared factors. To address this knowledge gap, we capitalized on the stability of genetic biomarkers through the lifetime, and on their unidirectional relationship with depression and cognition. Specifically, we determined the association between quantitative measures of cognitive function and depression and genetic instruments of insulin resistance traits in two large‐scale population samples, the Generation Scotland: Scottish Family Health Study (GS: SFHS; N = 19,994) and in the UK Biobank (N = 331,374). In the GS:SFHS, the polygenic risk score (PRS) for fasting insulin was associated with verbal intelligence and depression while the PRS for the homeostasis model assessment of insulin resistance was associated with verbal intelligence. Despite this overlap in genetic architecture, Mendelian randomization analyses in the GS:SFHS and in the UK Biobank samples did not yield evidence for causal associations from insulin resistance traits to either depression or cognition. These findings may be due to weak genetic instruments, limited cognitive measures and insufficient power but they may also indicate the need to identify other biological mechanisms that may mediate the relationship from insulin resistance to depression and cognition.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Pediatrics, Perinatology and Child Health
View Paper: https://www.semanticscholar.org/paper/42aa65ae3d7dffdcf1352435a76f8ebcd009ddc2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Genetics
Citations in the corpus
- NAD+ intermediates: The biology and therapeutic potential of NMN and NR (2017, neutral): “, 2011), these findings suggest that adipose tissue NAD could be a good therapeutic target for insulin resistance, which is an important risk factor of type 2 diabetes and cardiovascular disease (DeFronzo and Ferrannini, 1991; Reaven, 1988; Yamaguchi and Yoshino, 2017).”
- Trends in insulin resistance: insights into mechanisms and therapeutic strategy (2022, background): “In addition, increased physical activity is recommended to help increase energy expenditures and improve muscle insulin sensitivity, this two approach represent the fundamental treatment for IR.(14,15) The second step is the use of pharmacologic medications, including metformin, oral sulphonylureas,”
- Insulin resistance: Review of the underlying molecular mechanisms (2018, background): “Several hypotheses have been suggested for insulin hyperdegradation (Maberly et al., 1982), including via autoimmune antibodies against insulin or abnormal insulin structure due to mutations (Kasuga et al., 1999; Olatunbosun & Schade, 2017; Schlessinger, Obberghen, & Kahn, 1980).”
- New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis (2018, background): “All these effects contribute to disruption of insulin-stimulated glucose metabolism and increased risk of cardiovascular disease (CVD) in type 2 diabetics mellitus [85].”